Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14036057 | 0.93 | TSHR (0.44) | TSHRCYP2D6KMT2AHTR1AADRA1B | |
| SCHEMBL255945 | 0.91 | TSHR (0.42) | TSHRCYP2D6KMT2AHTR1AADRA1B | |
| SCHEMBL15032317 | 0.88 | TSHR (0.44) | TSHRCYP2D6KMT2AHTR1AADRA1B | |
| SCHEMBL6923193 | 0.88 | TSHR (0.47) | TSHRCYP2D6KMT2AKDM4EGAA | |
| SCHEMBL23559996 | 0.85 | TSHR (0.48) | TSHRCYP2D6KMT2AKDM4EGAA | |
| SCHEMBL25090104 | 0.80 | TSHR (0.52) | TSHRCYP2D6KMT2ASMN1; SMN2 | |
| SCHEMBL20261316 | 0.79 | TSHR (0.55) | TSHRCYP2D6SMN1; SMN2OPRM1 | |
| SCHEMBL19978213 | 0.77 | TSHR (0.53) | TSHRCYP2D6HSD11B1OPRM1 | |
| SCHEMBL25779023 | 0.77 | CYP2D6 (0.39) | TSHRCYP2D6KMT2AKDM4EGAA | |
| SCHEMBL143760 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280175-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280175-B2 | Hepatitis B antiviral agents | ZC3HAV1, HAVCR2, SLC10A1 | TSHR 2861/4885CYP2D6 937/4885KMT2A 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.